Filing Flows

Filing Flows › 8-K events › Jasper Therapeutics

Jasper Therapeutics: regulation fd disclosure

Form 8-K filed Nov 4, 2026 · items 3.03, 5.03, 7.01

FDA decisionsJasper Therapeutics Announces 1-for-30 Reverse Stock Split

What the filing says

Jasper Therapeutics Announces 1-for-30 Reverse Stock Split Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced a 1-for-30 reverse stock split (“Revers

Read the filing on SEC EDGAR →

What usually followsAcross 1,456 8-Ks reporting Item 3.03 (change to shareholders’ rights) in our universe, the stock's median move the next session was +0.1% (typical size ±1.5%, up 52% of the time); over the following 21 sessions, +1.2%. Item 5.03: +0.1% next session across 5,869. Every item ranked →

Other recent fda decisions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.